Southwest Securities released a research report on April 11 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the profit growth rate in 2023 exceeded expectations, and profitability was further improved; 2) “cinema+retail” diversified channel efforts to deepen the construction of an academic platform; 3) the steady progress of BD to create a new engine for growth. (Mainichi Keizai Shimbun)
西南证券4月11日发布研报称，给予济川药业（600566.SH）买入评级。评级理由主要包括：1）2023年利润增速超预期，盈利能力进一步提升；2）“院线+零售”多元渠道发力，深化学术平台搭建；3）BD稳步推进，打造增长新引擎。（每日经济新闻）
Southwest Securities released a research report on April 11 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the profit growth rate in 2023 exceeded expectations, and profitability was
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.